Syndax Pharmaceuticals Inc. Company Profile
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Syndax Pharmaceuticals at a glance
Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in New York, NY. Syndax Pharmaceuticals is led by Mr. Michael A. Metzger M.B.A. and employs about 298 people. The company's shares have traded publicly since 2016.
At a market capitalization of $1.52 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001395937, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Syndax Pharmaceuticals do?
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Business description based on the company's public filings.
Company information
- Legal name
- Syndax Pharmaceuticals Inc.
- Ticker
- NASDAQ: SNDX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael A. Metzger M.B.A.
- Employees
- 298
- Headquarters
- 730 Third Avenue, New York, NY, United States
- Phone
- 781 419 1400
- Website
- syndax.com
- IPO year
- 2016
- Market cap
- $1.52B
- SEC CIK
- 0001395937
- Latest annual report
- 10-K · Feb 26, 2026
Companies similar to Syndax Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PAHCPhibro Animal Health Corporation Class A | 37.40 | -0.85% | $1.52B | vs SNDX |
| KRSAKorsana Biosciences Inc. | 33.51 | +6.37% | $1.53B | vs SNDX |
| INVAInnoviva Inc. | 20.87 | -0.90% | $1.51B | vs SNDX |
| RAREUltragenyx Pharmaceutical Inc. | 15.29 | +2.69% | $1.51B | vs SNDX |
| STOKStoke Therapeutics Inc. | 23.95 | -1.40% | $1.55B | vs SNDX |
| QUREuniQure N.V. | 22.54 | -2.59% | $1.56B | vs SNDX |
| CMPSCOMPASS Pathways Plc American Depository Shares | 11.47 | -1.88% | $1.59B | vs SNDX |
| PCRXPacira BioSciences Inc. | 36.39 | +44.40% | $1.45B | vs SNDX |